University of Florida
This is a Phase I Study evaluating the safety and feasibility of IL-8 receptor-modified patient-derived activated CD70 CAR T cells in adult patients with brain metastases from primary cancer, with either newly diagnosed lesions or recurrent or progressive disease after prior therapy.
Adult patients with newly diagnosed or recurrent/progressive brain metastases will be screened. Consented patients will undergo screening procedures followed by tumor biopsy/surgery if clinically indicated, and may receive treatment for brain metastases, which include whole brain radiation therapy (WBRT), SRS treatment for new lesion(s) (SRS is permitted for recurrent disease only for newly developed brain lesion(s). Enrollment and administration of standard-of-care treatment will be coordinated such that each subject will not receive the CAR T-cell product until the preceding subject has comp…
Inclusion Criteria: * Histological confirmation of primary cancers * Histologic confirmation of CD70 on primary tumor, lymph node, or BM biopsy CD70-positive tumor expression confirmed by the investigational CD70 IHC assay defined as CD70 immunoreactivity in ≥ 5% of tumor cells at any staining intensity. * At least one recurrent or progressive metastatic lesion or new metastatic lesion(s). * KPS ≥ 70. * 18 years or older. * Adequate bone marrow and organ function as defined below: * CBC with differential with adequate bone marrow function as defined below: * Absolute neutrophil count (AN…
Single dose of 8R-70CAR T cells administered IV
CD70 expression will be assessed during screening using available tumor tissue obtained as part of routine clinical care from the primary tumor, lymph node, or brain metastasis, as applicable. The CD70 IHC result will be used to determine study eligibility. CD70 expression will be evaluated using an investigational immunohistochemistry (IHC) assay.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.